Quarterly ResultAug 4, 2026, 07:52 AM
Rhythm Pharma Q2 Revenue $71.3M; RM-718 Phase 2 Shows -11.6% BMI Reduction
AI Summary
Rhythm Pharmaceuticals reported Q2 2026 financial results with net product revenue of $71.3 million, a significant increase from $48.5 million in Q2 2025, and a net loss of $(50.4) million. Concurrently, the company announced positive preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity, showing an 11.6% mean BMI reduction at 16 weeks, comparable to other treatments. The U.S. launch of IMCIVREE for acquired HO is strong with over 400 patient start forms, contributing to a 19% sequential increase in global IMCIVREE sales.
Key Highlights
- Q2 2026 net product revenue was $71.3 million, up from $48.5 million YoY.
- Q2 2026 net loss attributable to common stockholders was $(50.4) million.
- RM-718 Phase 2 trial showed -11.6% mean BMI reduction at 16 weeks (n=7) in acquired HO.
- RM-718 efficacy was comparable to setmelanotide and bivamelagon.
- RM-718 was generally well tolerated with mild, localized hyperpigmentation.
- IMCIVREE U.S. launch for acquired HO received over 400 patient start forms by June 30, 2026.
- Global IMCIVREE sales increased 19% sequentially to $71.3 million.
- Cash, cash equivalents, and short-term investments totaled $330.9 million as of June 30, 2026.
- FY2026 Non-GAAP Operating Expenses guidance is $363 million to $397 million.
Price Impact
More from RYTM